This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Location/setting
UK/hospital and secondary care.
Methods

Analytical approach:
The analysis was based on a two-stage decision-analytic model, with a six-month decision tree followed by a Markov model up to a 15-year time horizon. The authors stated that the analysis was carried out from the perspective of the UK National Health Service (NHS).
Effectiveness data:
The clinical data came from a selection of relevant studies. The treatment effect for SCS with medical management, over five years, came from a published randomised controlled trial (RCT), which also provided the data on the longterm complications with SCS (Kemler, et al. 2000 , see 'Other Publications of Related Interest' below for bibliographic details). The key input was the achievement of at least a 50% reduction in pain on the visual analogue scale (VAS) and these data came directly from the RCT. Other data for the long-term transition probabilities came from observational studies identified by a systematic review.
Monetary benefit and utility valuations:
Most of the utility values were derived from responses to the European Quality of life (EQ-5D) questionnaire, and these were collected during the RCT.
Measure of benefit:
Quality-adjusted life-years (QALYs) were the summary benefit measure and they were discounted at an annual rate of 3.5%.
